NCT05617014
Alzheimer's Disease Neuroimaging Initiative 4
Enrolling by Invitation
Not specifiedAges 55–90ObservationalUniversity of Southern CaliforniaInvestigator-initiated
~1,500 participants
Updated 2026-07-06 on ClinicalTrials.gov
What's tested:NeuraceqAmyvidTauvidMK-6240NAV4694PI-2620
At a glance
Recruiting sites
0 of 62 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of enrollment of Underrepresented Populations (URPs)
Measured over 5 years
Conditions
Where it's being run
62 sites across 31 statesNew York8
California7
Florida5
Arizona3
Illinois3
Massachusetts3
Texas3
District of Columbia2
Study leadership
- Michael Weiner, MD · STUDY_DIRECTOR · University of California, San Francisco
- Paul Aisen, MD · PRINCIPAL_INVESTIGATOR · USC Alzheimer's Therapeutic Research Institute (ATRI)
- Ronald Petersen, MD, PHD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Rate of enrollment of Underrepresented Populations (URPs)5 years
The ADNI4 study aims to increased inclusion of underrepresented populations (URPs) to improve generalizability of results and advance our understanding of health disparities across URPs